Advanced Search
Contact | Corporate | Help

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Sponsors:
  • Johns Hopkins University
  • Genentech
Phases:
  • Phase I
  • Phase II
IndicationsAcronym:
LVO
  • Macular Edema
  • Retinal Vein Occlusion
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Intravitreal injection of ranibizumab .3 dose
  • Drug: Intravitreal injection of Ranibizumab .5 dose
Enrollment:
40

Additional information about NCT00407355.


SourceSolution © 2008-2012